Literature DB >> 23596462

Impact of age on markers of HIV-1 disease.

Vanessa Pirrone1, David J Libon, Christian Sell, Chad A Lerner, Michael R Nonnemacher, Brian Wigdahl.   

Abstract

Aging is a complicated process characterized by a progressive loss of homeostasis, which results in an increased vulnerability to multiple diseases. HIV-1-infected patients demonstrate a premature aging phenotype and develop certain age-related diseases earlier in their lifespan than what is seen in the general population. Age-related comorbidities may include the development of bone disease, metabolic disorders, neurologic impairment and immunosenescence. Age also appears to have an effect on traditional markers of HIV-1 disease progression, including CD4+ T-cell count and viral load. These effects are not only a consequence of HIV-1 infection, but in many cases, are also linked to antiretroviral therapy. This review summarizes the complex interplay between HIV-1 infection and aging, and the impact that aging has on markers of HIV-1 disease.

Entities:  

Keywords:  HIV-1; aging; comorbidities; disease progression; neurocognitive impairment

Year:  2013        PMID: 23596462      PMCID: PMC3625689          DOI: 10.2217/fvl.12.127

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  239 in total

1.  Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy.

Authors:  Leah Szadkowski; Alice Tseng; Sharon L Walmsley; Irving Salit; Janet M Raboud
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-03       Impact factor: 2.205

2.  [Evolution of a cohort of patients over 60 years old with HIV infection treated with highly-active antiretroviral therapy].

Authors:  Gabriel Vallecillo; Hernando Knobel; Ana Guelar; Pere Saballs
Journal:  Enferm Infecc Microbiol Clin       Date:  2005 Jun-Jul       Impact factor: 1.731

3.  Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Authors:  E J Wright; B Grund; K Robertson; B J Brew; M Roediger; M P Bain; F Drummond; M J Vjecha; J Hoy; C Miller; A C Penalva de Oliveira; W Pumpradit; J C Shlay; W El-Sadr; R W Price
Journal:  Neurology       Date:  2010-08-11       Impact factor: 9.910

4.  Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.

Authors:  Sonia Molina-Pinelo; Alejandro Vallejo; Laura Díaz; Natalia Soriano-Sarabia; Sara Ferrando-Martínez; Salvador Resino; María Angeles Muñoz-Fernández; Manuel Leal
Journal:  J Antimicrob Chemother       Date:  2009-07-16       Impact factor: 5.790

5.  Prevalence of cognitive disorders differs as a function of age in HIV virus infection.

Authors:  James T Becker; Oscar L Lopez; Mary Amanda Dew; Howard J Aizenstein
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

6.  Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis.

Authors:  R B Effros; R Allsopp; C P Chiu; M A Hausner; K Hirji; L Wang; C B Harley; B Villeponteau; M D West; J V Giorgi
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

7.  HIV-1 infected patients older than 50 years. PISCIS cohort study.

Authors:  G Navarro; M M Nogueras; F Segura; J Casabona; J M Miro; J Murillas; C Tural; E Ferrer; A Jaén; L Force; J Vilaró; I García; A Masabeu; J Altés; A Esteve; O Sued; M Riera; B Clotet; D Podzamczer; J M Gatell
Journal:  J Infect       Date:  2008-06-24       Impact factor: 6.072

8.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

9.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

10.  Premature aging of T cells is associated with faster HIV-1 disease progression.

Authors:  Weiwei Cao; Beth D Jamieson; Lance E Hultin; Patricia M Hultin; Rita B Effros; Roger Detels
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

View more
  7 in total

Review 1.  Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy.

Authors:  Daniela F Passos; Maria Rosa C Schetinger; Daniela Br Leal
Journal:  World J Virol       Date:  2015-08-12

2.  Risk factors for AIDS-defining illnesses among a population of poorly adherent people living with HIV/AIDS in Atlanta, Georgia.

Authors:  Jeremy Y Chow; Marcella Alsan; Wendy Armstrong; Carlos del Rio; Vincent C Marconi
Journal:  AIDS Care       Date:  2015-02-09

Review 3.  Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Authors:  Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal
Journal:  Purinergic Signal       Date:  2018-08-10       Impact factor: 3.765

4.  Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean Cohort.

Authors:  Gabriela Carriquiry; Mark J Giganti; Jessica L Castilho; Karu Jayathilake; Pedro Cahn; Beatriz Grinsztejn; Claudia Cortes; Jean W Pape; Denis Padgett; Juan Sierra-Madero; Catherine C McGowan; Bryan E Shepherd; Eduardo Gotuzzo
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

Review 5.  Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease.

Authors:  Monique E Maubert; Vanessa Pirrone; Nina T Rivera; Brian Wigdahl; Michael R Nonnemacher
Journal:  Front Microbiol       Date:  2016-01-11       Impact factor: 5.640

6.  The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.

Authors:  David I Dolling; Ruth L Goodall; Michael Chirara; James Hakim; Peter Nkurunziza; Paula Munderi; David Eram; Dinah Tumukunde; Moira J Spyer; Charles F Gilks; Pontiano Kaleebu; David T Dunn; Deenan Pillay
Journal:  BMC Infect Dis       Date:  2017-02-21       Impact factor: 3.090

Review 7.  The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.

Authors:  Hager Mohamed; Vandana Miller; Stephen R Jennings; Brian Wigdahl; Fred C Krebs
Journal:  J Immunol Res       Date:  2020-05-25       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.